Brought to you by:
FastWave Medical announces successful 30-day first-in-human data on peripheral IVL technology
FastWave Medical has announced the 30-day results of its first-in-human (FIH) study using the company’s differentiated peripheral intravascular lithotripsy (IVL) technology. This was a prospective, single-arm study to assess the safety and feasibility of the FastWave IVL system in patients…
A proposal to save vascular surgery
In response to recent articles in the lay press suggesting vascular surgeons were performing unnecessary procedures, Vascular Specialist medical editor, Malachi Sheahan, has asked me to write an editorial based on a talk I presented at the 2023 VEITHsymposium. At…
Viabahn use in claudicants with long, complex SFA lesions ‘safe and effective’ through five years
Recently published research indicates that stent grafting with the Viabahn endoprosthesis (W L Gore & Associates) of long and complex superficial femoral artery (SFA) lesions in patients with claudication is a safe and effective long-term treatment option. Writing in the Journal of Vascular…
Endologix announces completion of enrollment in TORUS 2 study for PAD in SFA
Endologix has completed enrollment in the TORUS 2 investigational device exemption (IDE) clinical study in the U.S., a press release reports. The TORUS 2 study is a prospective, single-arm trial of 188 patients to evaluate safety and effectiveness of the Torus stent…
IN.PACT Admiral DCB performs well across wide range of clinical, anatomical scenarios in pooled analysis
In a pooled analysis of the predictors of drug-coated balloon (DCB) effectiveness, the IN.PACT Admiral DCB (Medtronic) performed well across a broad range of clinical, anatomical and procedural scenarios. This is according to Prakash Krishnan, MD, an interventional cardiologist at Mount Sinai…